Literature DB >> 16799072

Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis.

Katie Ewer1, Kerry A Millington, Jonathan J Deeks, Lydia Alvarez, Gerry Bryant, Ajit Lalvani.   

Abstract

RATIONALE: The kinetics of Mycobacterium tuberculosis-specific Th1-type T-cell responses after M. tuberculosis infection are likely to be important in determining clinical outcome.
OBJECTIVE: To investigate the kinetics of T-cell responses, in the context of a point-source school tuberculosis outbreak, in three groups of contacts who differed by preventive treatment status and tuberculin skin test (TST) results: 38 treated TST-positive students, 11 untreated TST-positive staff, and 14 untreated students with negative or borderline TST results.
METHODS: We used the ex vivo IFN-gamma enzyme-linked immunospot assay (ELISpot) to track T cells specific for two region of difference 1 (RD1) antigens, early secretory antigenic target 6 and culture filtrate protein 10, for 18 mo after cessation of tuberculosis exposure. MAIN
RESULTS: The treated TST-positive students had an average 68% decline in frequencies of RD1-specific IFN-gamma-secreting T cells per year (p < 0.0001) and 6 of 38 students had no detectable RD1-specific T cells by 18 mo. No change in frequencies of these cells was observed in the untreated TST-positive staff (p = 0.38) and none were ELISpot-negative at 18 mo. Of the 14 untreated students, 7 were persistently ELISpot-positive (all of whom had borderline TST results), and 7 became ELISpot-negative (all but one had negative TST results) during follow-up.
CONCLUSIONS: The decrease in M. tuberculosis-specific T cells and their disappearance in a proportion of treated students likely reflect declining antigenic and bacterial load in vivo induced by antibiotic treatment. The observed disappearance of M. tuberculosis-specific T cells in the untreated TST-negative contacts suggests that an acute resolving infection may occur in some contacts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799072     DOI: 10.1164/rccm.200511-1783OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  76 in total

1.  Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease.

Authors:  S A Clark; S L Martin; A Pozniak; A Steel; B Ward; J Dunning; D C Henderson; M Nelson; B Gazzard; P Kelleher
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

2.  Follow-up study of tuberculosis-exposed supermarket customers with negative tuberculin skin test results in association with positive gamma interferon release assay results.

Authors:  Willeke P J Franken; Ben F P J Koster; Ailko W J Bossink; Steven F T Thijsen; John J M Bouwman; Jaap T van Dissel; Sandra M Arend
Journal:  Clin Vaccine Immunol       Date:  2007-07-11

3.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Authors:  Clare R Sander; Ansar A Pathan; Natalie E R Beveridge; Ian Poulton; Angela Minassian; Nicola Alder; Johan Van Wijgerden; Adrian V S Hill; Fergus V Gleeson; Robert J O Davies; Geoffrey Pasvol; Helen McShane
Journal:  Am J Respir Crit Care Med       Date:  2009-01-16       Impact factor: 21.405

4.  Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes.

Authors:  Madhukar Pai
Journal:  Nat Rev Microbiol       Date:  2010-01-19       Impact factor: 60.633

5.  Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection.

Authors:  David Doberne; Rajiv L Gaur; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

Review 6.  Early clearance of Mycobacterium tuberculosis: a new frontier in prevention.

Authors:  Ayesha J Verrall; Mihai G Netea; Bachti Alisjahbana; Philip C Hill; Reimout van Crevel
Journal:  Immunology       Date:  2014-04       Impact factor: 7.397

7.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

8.  Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results.

Authors:  Nira R Pollock; Suely S Kashino; Danielle R Napolitano; Alex Sloutsky; Swati Joshi; Jasmine Guillet; Michael Wong; Edward Nardell; Antonio Campos-Neto
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

9.  Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.

Authors:  Elitza S Theel; Heather Hilgart; Margaret Breen-Lyles; Kevin McCoy; Rhiannon Flury; Laura E Breeher; John Wilson; Irene G Sia; Jennifer A Whitaker; Jeremy Clain; Timothy R Aksamit; Patricio Escalante
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

10.  IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia.

Authors:  Helena del Corral; Sara C París; Nancy D Marín; Diana M Marín; Lucelly López; Hanna M Henao; Teresita Martínez; Liliana Villa; Luis F Barrera; Blanca L Ortiz; María E Ramírez; Carlos J Montes; María C Oquendo; Lisandra M Arango; Felipe Riaño; Carlos Aguirre; Alberto Bustamante; John T Belisle; Karen Dobos; Gloria I Mejía; Margarita R Giraldo; Patrick J Brennan; Jaime Robledo; María P Arbeláez; Carlos A Rojas; Luis F García
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.